Unity Biotechnology (UBX) AI Stock Analysis

• Market Cap: $13.36M
• Dividend Yield: N/A
• Average Volume (3M): 433.10K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.87
• Revenue Growth: N/A
• EPS Growth: 35.08%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -0.43
• Shares Outstanding: 17,212,172
• 10 Day Avg. Volume: 943,254
• 30 Day Avg. Volume: 433,102
• PEG Ratio: 0.12
• Price to Book (P/B): -92.17
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.87
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $2.33
• Price Target Upside: 194.94% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 31 Underperform
• Price Target: ―

Unity Biotechnology's overall score is weighed down by significant financial challenges, including persistent losses and negative equity. Technical analysis suggests a bearish trend with limited momentum. Valuation metrics reflect the unprofitability of the company. However, the recent strategic appointment to the Board provides a potential strategic advantage in its program development.

Positive Factors

Clinical Trial Results

UBX1325 demonstrated vision gains comparable and statistically non-inferior to aflibercept at week 36 considering difficult-to-treat DME patients with favorable safety and tolerability.

Study Outcomes

The Phase 2 BEHOLD study demonstrated statistically significant 48-week benefit in DME with mean change in BCVA +6.2 ETDRS letters from baseline.

Treatment Efficacy

UBX1325 generally outperformed aflibercept in the pre-specified subgroup entering the study with CST <400 microns, reflecting 60% of enrolled patients.

Negative Factors

Clinical Trial Imbalance

There were considerably more Vabysmo (faricimab) patients in the UBX1325 group, compared to aflibercept, reflecting a relevant imbalance.

Management Changes

The recent management changes including transition of the roles of CEO, CFO, and Chief Legal Officer moving into consulting roles as the company evaluates strategic alternatives.

Study Endpoint Miss

The previously announced primary endpoint miss for the Phase 2B ASPIRE study comparing UBX1325 and aflibercept in diabetic macular edema patients, not achieving non-inferiority at the average of weeks 20 and 24 primary analysis.

Unity Biotechnology Business Overview & Revenue Model

Company Description

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

How the Company Makes Money

Unity Biotechnology makes money through the development and commercialization of its therapeutic products targeting senescent cells. The company's revenue model primarily relies on milestone payments, licensing deals, and potential royalties from partnerships with larger pharmaceutical companies. Unity may also generate income from collaborations with other biotech firms or research institutions, which can provide funding for research and development activities. Additionally, the company might raise capital through public or private investments to support its ongoing research and clinical trials, which are crucial for bringing its products to market.

Unity Biotechnology Financial Statement Overview

Summary

Unity Biotechnology is struggling with financial challenges, reflected in its income statement, balance sheet, and cash flow. The lack of revenue growth, persistent losses, and negative equity highlight significant operational and financial risks. The company must focus on improving its revenue generation and managing expenses to achieve financial stability.

Income Statement

Unity Biotechnology has faced challenges with generating revenue, as indicated by repeated periods with zero or negative sales. The company has been unable to achieve profitability, with consistently negative EBIT and net income. This reflects ongoing operational difficulties and a need to establish sustainable revenue streams.

Balance Sheet

The balance sheet shows a concerning financial position, with negative stockholders' equity in the most recent period. The debt-to-equity ratio is not applicable due to negative equity, and the persistent decline in equity suggests financial instability. Despite a decrease in total assets, the company has managed to reduce its total liabilities.

Cash Flow

Operating cash flow remains negative, indicating ongoing cash burn. The free cash flow situation is concerning, showing no improvement. Although there is some cash inflow from investing activities, it is insufficient to offset the negative operating cash flow. The company's sustainability depends on its ability to manage cash effectively.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	236.00K	4.78M	0.00
	Gross Profit
227.00K	0.00	-19.70M	-1.94M	1.90M	-3.45M
	EBIT
-29.96M	-31.17M	-44.67M	-57.57M	-56.66M	-93.93M
	EBITDA
-32.32M	-25.12M	-37.28M	-38.73M	-54.67M	-89.10M
	Net Income Common Stockholders
-27.50M	-25.99M	-39.86M	-57.75M	-60.04M	-91.87M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
16.93M	23.23M	43.20M	94.80M	88.08M	97.70M
	Total Assets
30.35M	37.66M	65.69M	124.35M	124.71M	156.32M
	Total Debt
18.68M	23.54M	26.99M	47.36M	51.56M	58.98M
	Net Debt
10.68M	15.96M	7.19M	34.62M	18.65M	41.17M
	Total Liabilities
30.55M	31.17M	37.29M	57.50M	65.14M	73.44M
	Stockholders Equity
-205.00K	6.49M	28.40M	66.85M	59.57M	82.88M
Cash Flow		Free Cash Flow
-22.04M	-20.86M	-37.10M	-51.13M	-45.26M	-78.98M
	Operating Cash Flow
-22.04M	-20.86M	-38.65M	-51.03M	-45.06M	-78.33M
	Investing Cash Flow
22.53M	8.56M	60.49M	-24.55M	39.31M	-5.21M
	Financing Cash Flow
77.00K	77.00K	-16.34M	54.85M	20.84M	63.88M

Unity Biotechnology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.79
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UBX, the sentiment is Negative. The current price of 0.79 is above the 20-day moving average (MA) of 0.75, below the 50-day MA of 0.87, and below the 200-day MA of 1.34, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 46.77 is Neutral, neither overbought nor oversold. The STOCH value of 27.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UBX.

Unity Biotechnology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.24B	3.26	-44.35%	6.48%	16.78%	-0.10%
CANF	42 Neutral	$14.64M	―	-122.28%	―	―	―
EQ	41 Neutral	$11.52M	―	-88.32%	―	-19.76%	-13.20%
SNSE	40 Underperform	$8.26M	―	-64.18%	―	―	1.00%
PMN	38 Underperform	$16.34M	―	-19.56%	―	―	98.61%
EDSA	35 Underperform	$14.12M	―	-58.78%	―	―	-126.54%
UBX	31 Underperform	$13.36M	―	-231.27%	―	―	35.08%

Unity Biotechnology Corporate Events

Unity Biotechnology Appoints Dr. Yehia Hashad to Board

On March 8, 2025, UNITY Biotechnology appointed Dr. Yehia Hashad to its Board of Directors and Science Committee. Dr. Hashad, an experienced ophthalmologist and executive at Bausch + Lomb, brings over 25 years of leadership in global research and development. His expertise is expected to aid UNITY in advancing its UBX1325 program for diabetic macular edema and other ophthalmologic treatments, potentially enhancing the company’s strategic positioning in the biotechnology sector.